Stock Events

Stock Events

IO Biotech 

$0.01
50
+$0+3% Tuesday 19:30

Statistics

Day High
0.01
Day Low
0
52W High
2.79
52W Low
0
Volume
167,100
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14NovExpected
Q4 0
Q3 2025
-0.32
-0.26
-0.19
-0.13
Expected EPS
-0.324
Actual EPS
-0.13

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IOBTQ. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech SE is a competitor because it also focuses on developing immunotherapies for cancer and other serious diseases, similar to IO Biotech's focus on novel immune-modulating cancer therapies.
Moderna
MRNA
Mkt Cap17.99B
Moderna, Inc. is involved in creating mRNA-based therapies, including cancer vaccines, which puts it in direct competition with IO Biotech's immunotherapy research.
Novavax
NVAX
Mkt Cap1.32B
Novavax, Inc. competes in the development of vaccines for serious infectious diseases but its technology and approach to stimulating immune responses can be seen as competitive to IO Biotech's work in cancer immunotherapy.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. has a broad portfolio including oncology, making it a competitor due to its involvement in developing treatments for cancer, similar to IO Biotech's focus.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. is a biotechnology company with efforts in oncology and therapeutics that could compete with IO Biotech's cancer immunotherapy products.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a diverse range of biopharmaceutical products, including cancer treatments, making it a competitor in the oncology space alongside IO Biotech.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb Company is heavily involved in cancer research and drug development, positioning it as a competitor to IO Biotech in the oncology market.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is a leading pharmaceutical company with a strong emphasis on cancer treatments, including immunotherapy, making it a direct competitor to IO Biotech.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG engages in the research and development of medical drugs, including cancer immunotherapies, which competes with IO Biotech's focus area.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca PLC is involved in the discovery and development of new cancer treatments, including immunotherapies, making it a competitor in the same field as IO Biotech.

About

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Show more...
CEO
Dr. Mai-Britt Zocca Ph.D.
Employees
80
Country
United States
ISIN
US4497781090

Listings

OTC Link
US
IOBTQ
XNAS
US
IOBT
BOATS
BOATS
IOBT.BOATS

0 Comments

Share your thoughts

FAQ

What is IO Biotech stock price today?▼
The current price of IOBTQ is $0.01 USD — it has increased by +3% in the past 24 hours. Watch IO Biotech stock price performance more closely on the chart.
What is IO Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange IO Biotech stocks are traded under the ticker IOBTQ.
What were IO Biotech earnings last quarter?▼
IOBTQ earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.32 USD resulting in a +59.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does IO Biotech have?▼
As of May 06, 2026, the company has 80 employees.
In which sector is IO Biotech located?▼
IO Biotech operates in the Health & Wellness sector.
When did IO Biotech complete a stock split?▼
IO Biotech has not had any recent stock splits.
Where is IO Biotech headquartered?▼
IO Biotech is headquartered in Copenhagen, United States.